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Abstract
We have recently identified in a transgenic mouse model of Alzheimer’s disease (AD) membrane-type 5-MMP
(MT5-MMP) as a new player in Alzheimer’s pathogenesis, which displays pro-amyloidogenic features and proteolytic
processing of amyloid precursor protein (APP). Another group has reported that MT5-MMP processing of APP may
release a novel neurotoxic APP fragment. Although MT5-MMP-mediated APP processing appears to be a key
pathogenic step, we hypothesize that MT5-MMP may also contribute to AD pathogenesis through complementary
mechanisms that involve the activation of pro-inflammatory pathways and/or APP trafficking.
Keywords: Matrix metalloproteinases, Neurodegenerative disease, Trafficking, Neuroinflammation, IL-1β,
Amyloidogenesis, Amyloid precursor protein
Background
MT5-MMP belongs to the multigenic family of Zn2+
MMPs, which have been extensively associated with
different physiological and pathological settings [1, 2].
MT5-MMP was first isolated from mouse brain tissue
and from glioblastoma by two laboratories in 1999 [3,
4]. MT5-MMP is predominantly expressed in the ner-
vous system [5], mainly in neurons, and to a lesser
extent also in astrocytes and microglial and endothelial
cells [6–8]. MT5-MMP is a 645 amino acid transmem-
brane glycosylated proteinase that is intracellularly
activated by the Ca2+-dependent proprotein convertase
furin. The latter can also cleave MT5-MMP above its
transmembrane domain before it reaches the plasma
membrane, thus leading to the release of a truncated
active soluble form of MT5-MMP [9]. MT5-MMP
harbors nuclear localization sequences that may tag the
proteinase for import into the nucleus [10]. The
proteolytic activity of MT5-MMP is mainly under the
control of the endogenous tissue inhibitor of MMP-2
(TIMP-2). Alternatively, adaptor proteins such as
Mint-3 regulate MT5-MMP activity by controling its
recycling from the trans-golgi network to the cell
membrane and its localization in cells [11]. Moreover,
MT5-MMP can be targeted to synapses through inter-
action with proteins containing PDZ domains such as
the AMPA receptor binding protein (ABP) and the
glutamate receptor interacting protein (GRIP) [12].
Overall, MT5-MMP appears as a functionally versatile
molecule by virtue of its multiple interactions and
localizations in the intracellular and pericellular com-
partments. An open question is whether MT5-MMP
may in turn influence the subcellular localization and
activity of its interacting proteins, and should be
considered as a “moonlighting protein.” One recent
example among MMPs concerns MMP-12, which
besides its well-known proteolytic activity has also
transcription factor properties [13].
We are just starting to understand the functional
diversity of MT5-MMP in pathology. Early studies
showed the ability of MT5-MMP to proteolytically
activate MMP-2 [3] and to process KiSS-1 protein and
KISS-1-derived decapeptide metastin [14], which overall
promotes cancer progression. MT5-MMP has been also
reported to stimulate neuropathic pain by promoting
aberrant axonal sprouting in the spinal cord after sciatic
nerve injury in mice [15]. Moreover, it has been
suggested that MT5-MMP is necessary for the inflam-
matory response to interleukin-1 beta (IL-1β) and tumor
necrosis factor-alpha (TNF-α) in the peripheral nervous
system [16]. It is noteworthy that no overt developmental
abnormalities have been detected in MT5-MMP−/− mice,
in contrast with the clearly marked phenotypes they
display in pathological conditions [15–17], and also in* Correspondence: santiago.rivera@univ-amu.fr
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contrast with other members of the MT-MMP family
such as MT1-MMP. This could imply that modulating
MT5-MMP activity in pathology may have limited impact
on physiology and highlights the therapeutic potential of
targeting MT5-MMP.
MT5-MMP in Alzheimer’s disease
MT5-MMP was first related to AD in a study showing
the expression of the proteinase in dystrophic neurites
around senile plaques in post-mortem AD brains [18].
The ability of MT5-MMP to process APP into different
truncated APP fragments was later demonstrated [19].
More recently, two teams, including ours, reported the
possible implication of MT5-MMP in AD by means of
its functional interaction with APP [17, 20]. Willem and
collaborators showed that MT5-MMP cleavage of APP
upstream of the beta-site amyloid precursor protein
cleaving enzyme 1 (BACE-1), combined with cleavage by
the α-secretase ADAM-10, generates a so-called Aη-α
fragment, which inhibits long-term potentiation (LTP) in
vitro [20]. In parallel, we provided in vivo evidence that
MT5-MMP deficiency is associated with a robust and
durable amelioration of the pathological outcome in the
5xFAD transgenic mouse model of AD. Compared to
5xFAD mice, bigenic 5xFAD/MT5-MMP−/− exhibited
strong decreases of amyloid beta peptide (Aβ) load, glio-
sis and IL-1β levels, and a better preservation of the
neuronal network. Moreover, cognitive and LTP dys-
functions were prevented in bigenic mice [17]. In the
same study, we demonstrated that MT5-MMP
interacts with APP and stimulates the formation of Aβ
and the toxic C99 APP fragment. Together, these
results unveil the contribution of MT5-MMP to AD
pathogenesis and strongly suggest its involvement at
least in APP processing. However, two complementary
non-exclusive mechanistic hypotheses may be put for-
ward on the pathogenic effects of MT5-MMP in AD:
Hypotheses
(1)The pro-amyloidogenic features of MT5-MMP
could result from interactions with APP, which
would stimulate its trafficking into endosomes,
not necessarily in a proteolytic-dependent manner.
These organelles are considered to be the main loci
of Aβ production [21]. Testing this hypothesis would
require to modulate the activity/presence of MT5-
MMP by gain/loss of function in a cellular system
and determine by imaging and biochemical
approaches how this might change the distribution
of APP and/or Aβ species in the endosomal/
lysosomal compartments.
(2)The pathogenic role of MT5-MMP in AD could
also result from its contribution to the chronic
neuroinflammatory process that aggravates AD
pathogenesis. Reduced glial reactivity and IL-1β
levels found in our bigenic 5xFAD/MT5-MMP−/−
mice [17] could simply result from MT5-MMP
deficiency and consequent reduced Aβ load, but
we cannot exclude that MT5-MMP inhibition
could actually reduce neuroinflammation in an
amyloid-independent manner. This idea is consistent
with the two following findings: (a) intraplantar
injections of IL-1β or TNF-α in MT5-MMP−/−
mice do not induce the pro-inflammatory response
commonly observed in wild-type mice [16]. The
underlying mechanism involves a deficient processing
of N-cadherin, which is a substrate of MT5-MMP,
Fig. 1 Scheme summarizing some known and some hypothetical functions of MT5-MMP in nervous system pathophysiology. Solid lines/frames
represent biological actions and functional interactions reported in the literature. Dotted lines/insets represent the alternative/complementary
hypotheses we propose herein. APP: amyloid precursor protein; ABP: AMPA receptor binding protein; CNS: central nervous system; GRIP:
glutamate receptor interacting protein; IL-1β: interleukin-1 beta; PNS: peripheral nervous system; TNF-α: tumor necrosis factor-alpha
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and this appears to alter the communication between
mast cells and peripheral sensory neurons. (b) The
combined proteolytic action of MT5-MMP and
α-secretase on APP can release under certain
conditions a N-terminally elongated Aβ form, the
neurotoxic Aη-α peptide [20]. Aη-α generation could
have a neuroinflammatory effect associated with its
neurotoxicity, but also a consubstantial reduction of
the pool of soluble APP-α (sAPPα) generated by the
solely action of α-secretase, and reported to be
neuroprotective [22]. Whether MT5-MMP exerts
pro-inflammatory activity in the brain could be tested
by challenging neural cell cultures deficient for
MT5-MMP with pro-inflammatory agents and
determine whether well-known responsive genes
are transcriptionally activated. Alternatively, the
same experimental readout could be used after
icv administration of the cytokines of interest in
MT5-MMP−/− brains. This idea could be further
tested in young bigenic 5xFAD/MT5-MMP−/−
mice before Aβ accumulation.
Implications of the hypotheses
The confirmation of the first hypothesis will uncover
MT5-MMP as a multifunctional enzyme with proteolytic
and non-proteolytic features, which could both ultim-
ately stimulate APP metabolism and amyloidogenesis.
The confirmation of the second hypothesis would add
MT5-MMP to the list of MMPs that promote inflamma-
tion in the central nervous system and most interestingly
would indirectly support the idea that neuroinflammation
is a triggering event of the pathogenic process in AD.
Confirming both hypotheses should place MT5-MMP at
the crossroads of amyloidogenesis and neuroinflammation,
thus providing ground for a better comprehension of AD
pathophysiology (see Fig. 1). In turn, such confirmation
would pave the way for the development of innovative
therapeutic strategies based on the modulation of MT5-
MMP, which should take into account the diversity of its
biological actions.
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